¥25,503.05
+¥837.30(+3.39%)
*データ最終更新日:2026-07-03 11:37(UTC+8)
2026-07-03 11:37時点で、Becton Dickinson & Co(BDX)の価格は¥25,503.05、時価総額は¥8.84T、PERは25.19、配当利回りは2.47%です。 本日の株価は¥23,499.33から¥25,607.91の間で変動しました。現在の価格は本日安値より8.52%高く、本日高値より0.40%低く、取引高は2.05Mです。 過去52週間で、BDXは¥22,586.00から¥30,994.72の間で取引されており、現在の価格は52週間高値より-17.71%低い水準にあります。
BDX 主な統計情報
前日終値¥25,035.99
時価総額¥8.84T
取引量2.05M
P/E比率25.19
配当利回り(TTM)2.47%
配当額¥169.40
希薄化EPS(TTM)4.05
純利益(FY)¥270.71B
収益(FY)¥3.52T
決算日2026-08-06
EPS予想3.13
収益予測¥788.33B
発行済株式数353.29M
ベータ(1年)0.278
権利落ち日2026-06-09
配当支払日2026-06-30
BDXについて
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
セクターHealthcare
業界Medical - Instruments & Supplies
CEOThomas E. Polen Jr.
本社Franklin Lakes,NJ,US
公式ウェブサイトhttps://www.bd.com
従業員数(FY)72.00K
平均収益(1年)¥48.93M
従業員一人当たりの純利益¥3.75M
Becton Dickinson & Co (BDX) の詳細についてさらに知る
ブログ
After BDX Surges 215%: Privacy Sector Revival or Low Liquidity Pricing?Beldex (BDX) has surged over 215% in the past 30 days, pushing its market capitalization past $3.7 billion. However, its 24-hour trading volume remains extremely low.2026-05-29

Why Might a Phased Liquidity Upgrade Trigger Structural Repricing for BDX?As a blockchain network positioned around privacy infrastructure and cross-chain interoperability, BDX has long sought to balance exchange liquidity with ecosystem expansion.2026-03-03

BDX Token Price Prediction 2026: Can This Rising Privacy Coin Break Through? In-Depth AnalysisPrivacy has become an increasingly valuable asset in the digital age, and the Beldex project is dedicated to building the infrastructure to protect it.2026-01-28

Becton Dickinson & Co(BDX)よくある質問
今日のBecton Dickinson & Co(BDX)の株価はいくらですか?
x
Becton Dickinson & Co(BDX)は現在¥25,503.05で取引されており、24時間の変動率は+3.39%です。52週の取引レンジは¥22,586.00~¥30,994.72です。
Becton Dickinson & Co(BDX)の52週間の高値と安値はいくらですか?
x
Becton Dickinson & Co(BDX)の株価収益率(P/E比率)はいくらですか? この指標は何を示していますか?
x
Becton Dickinson & Co(BDX)の時価総額はいくらですか?
x
Becton Dickinson & Co(BDX)の直近の四半期ごとの1株当たり利益(EPS)はいくらですか?
x
今、Becton Dickinson & Co(BDX)を買うべきか、売るべきか?
x
Becton Dickinson & Co(BDX)の株価に影響を与える要因は何ですか?
x
Becton Dickinson & Co(BDX)株の購入方法
x
リスク警告
株式市場は高いリスクと価格変動を伴います。投資の価値は上昇または下落する可能性があり、投資元本の全額を回収できない場合があります。過去の実績は将来の結果を保証するものではありません。投資判断を行う前に、ご自身の投資経験、財務状況、投資目的、リスク許容度を十分に評価し、独自に調査を行ってください。必要に応じて、独立したファイナンシャルアドバイザーにご相談ください。
免責事項
本ページの内容は情報提供のみを目的としており、投資助言、財務上の助言、または取引推奨を構成するものではありません。Gateは、かかる財務上の意思決定に起因するいかなる損失または損害についても責任を負いません。また、Gateは、アメリカ合衆国、カナダ、イラン、キューバを含むがこれらに限られない一部の市場および法域において、完全なサービスを提供できない場合があることにご留意ください。制限対象地域に関する詳細は、ユーザー契約をご参照ください。






